Richard Pollard, M.D.
Chief, Infectious Diseases
UCD Med Center
Sacramento Campus

Representative Publications

Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HFJr, Martin JN, Deeks SG, and Shacklett BL. Immunodominant HIV-Specific CD8 +T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. Journal of Virology, 84(19): 10354-10365, 2010.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P, and the STARTMRK Investigators. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. Journal of Acquired Immune Deficiency Syndrome, 2010 Apr 15. [Epub ahead of print], 2010.

Smith K, Zheng L, Bosch R, Margolis D, Tenorio A, Napolitano L, Saag M, Connick E, Lawrence J, Gross B, Francis I, Valdez H, Wang R, Muurahainen N, Stocker V, Pollard RB.. Treatment with recombinant growth hormone is associated with enhanced CD4 lymphocyte reconstitution in HIV-infected subjects with incomplete immune reconstitution on HAART--results of adult AIDS clinical trial group protocol (AACTG) 5174. AIDS Res Human Retrovir, 26(4): 425-432, 2010.

Kalayjian R, Machekano R, Rizk N, Robbins G, Gandhi R, Rodriguez B, Pollard RB, Lederman M, and Landay A. Pre-treatment levels of soluble receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. Journal of Infectious Diseases, 201(12): 1796-1805, 2010.

Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; and the AIDS Clinical Trials Group A5192 Team.. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. Journal of Infectious Diseases, 201(11): 1686-1696, 2010.

Schacker T, Bosch R, Bennett K, Pollard RB, Robbins G, Collier A, Gulick R, Spritzler J, and Mildvan D. Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV. Journal of Acquired Immune Deficiency Syndrome, 54(1): 59-62, 2010.

Crawford K, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard RB, Stocker V, Lederman M, Flexner C.. Age-related changes in pharmacokinetic parameters of the HIV protease inhibitor lopinavir. AIDS Res Human Retrovir, 2009.

Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL, and Kalayjian RC. Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral-Naive HIV-Infected Subjects. The Journal of Infectious Diseases, 200: 614-618, 2009.

Yoshida T, Kobayashi M, Li XD, Pollard RB, and Suzuki F. Inhibitory effect of glycyrrhizin on the neutrophil-dependent increase of R5 HIV replication in cultures of macrophages. Immunology and Cell Biology, 2009(Jun 16): Epub ahead of print, 2009.

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, and Altfeld M. Sex differences in the TLR-mediated response of pDCs to HIV-1 are associated with higher immune activation in infected women. Nature Medicine, 15(8): 955-959, 2009.